Huang Wen-Yen, Ho Ching-Liang, Lee Chia-Cheng, Hsiao Cheng-Wen, Wu Chang-Chieh, Jao Shu-Wen, Yang Jen-Fu, Lo Cheng-Hsiang, Chen Jia-Hong
Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
PLoS One. 2017 Mar 22;12(3):e0174280. doi: 10.1371/journal.pone.0174280. eCollection 2017.
The purpose of this study was to estimate the impact of metronomic therapy with oral tegafur-uracil (UFUR) following an intravenous FOLFOX regimen as surgical adjuvant chemotherapy on the overall survival (OS) and disease-free survival (DFS) of stage III colon cancer patients. From the retrospective database of patients who underwent a surgical resection for colorectal cancer at the Tri-Service General Hospital from October 2008 through December 2014, stage III colon carcinomas treated with radical R0 resection were reviewed. One hundred thirty two patients were treated with a FOLFOX regimen (comparison group), and 113 patients were treated with the same regimen followed by additional oral UFUR (UFUR group). The clinical characteristics and mean age of the comparison and UFUR groups were similar. Furthermore, for all study patients, DFS was not significantly different between the two groups. However, 5-year OS rates were 86.8% and 68.5% in the UFUR and comparison groups, respectively (p = 0.0107). Adding UFUR to a FOLFOX regimen was found to significantly improve the OS in patients with stage III colon cancer. UFUR as a maintenance therapy following FOLFOX regimen as an alternative therapeutic option for the treatment of stage III colon cancer patients.
本研究的目的是评估在静脉注射FOLFOX方案后采用口服替加氟-尿嘧啶（优福定，UFUR）进行节拍化疗作为手术辅助化疗对III期结肠癌患者总生存期（OS）和无病生存期（DFS）的影响。从2008年10月至2014年12月在三军总医院接受结直肠癌手术切除患者的回顾性数据库中，对接受根治性R0切除的III期结肠癌进行了回顾。132例患者接受FOLFOX方案治疗（对照组），113例患者接受相同方案治疗后加用口服UFUR（UFUR组）。对照组和UFUR组的临床特征和平均年龄相似。此外，对于所有研究患者，两组之间的DFS无显著差异。然而，UFUR组和对照组的5年OS率分别为86.8%和68.5%（p = 0.0107）。发现在FOLFOX方案中加用UFUR可显著改善III期结肠癌患者的OS。UFUR作为FOLFOX方案后的维持治疗，可作为III期结肠癌患者治疗的一种替代治疗选择。
